木犀草素 (LUT) 是一种天然存在的黄酮类化合物，存在于蔬菜、水果和草药中，其药理活性已被广泛研究，包括对各种癌细胞系的抗增殖和抗癌作用。它还表现出有效的抗氧化特性和针对人类癌症的促凋亡活性。然而，其治疗潜力因其在水中的溶解度差（45°C 下为 5 μg/ml）和生物利用度低而受到阻碍。这项开发木犀草素纳米载体的研究旨在克服这些局限性，从而为癌症治疗开辟新的可能性。本文涵盖了几种旨在提高 LUT 溶解度和生物利用度的纳米制剂。影响木犀草素溶解度和生物利用度的纳米制剂的理化特性已成为更深入研究的主题。此外，它还研究了 LUT 的抗炎和抗氧化特性如何帮助减轻化疗的副作用。大多数纳米制剂，包括植物体、脂质纳米颗粒、脂质体、蛋白质纳米颗粒、聚合物胶束、纳米乳液和金属纳米颗粒，在改善LUT 的溶解度和生物利用度。这是增强 LUT 在癌症治疗中的治疗潜力方面向前迈出的重要一步。此外，研究发现LUT清除自由基的能力可以显着减少癌症治疗的副作用，进一步凸显其改善患者治疗效果的潜力。纳米制剂由于其独特的表面和理化特性，提高了LUT的溶解度和生物利用度。然而，为了在肿瘤学中实现 LUT 的良好临床表现，需要解决纳米制剂较差的体外和体内相关性和可扩展性问题。版权所有 © Bentham Science Publishers；如有任何疑问，请发送电子邮件至 epub@benthamscience.net。

Luteolin (LUT), a naturally occurring flavonoid found in vegetables, fruits, and herbal medicines, has been extensively studied for its pharmacological activities, including anti-proliferative and anticancer effects on various cancer lines. It also exhibits potent antioxidant properties and pro-apoptotic activities against human cancers. However, its therapeutic potential is hindered by its poor solubility in water (5 μg/ml at 45°C) and low bioavailability. This research on the development of luteolin-loaded nanocarrier aims to overcome these limitations, thereby opening up new possibilities in cancer treatment.This paper covers several nanoformulations studied to increase the solubility and bioavailability of LUT. The physicochemical characteristics of the nanoformulation that influence luteolin's solubility and bioavailability have been the subject of more in-depth investigation. Furthermore, it examines how LUT's anti-inflammatory and antioxidant properties aid in lessening the side effects of chemotherapy.Most nanoformulations, including phytosomes, lipid nanoparticles, liposomes, protein nanoparticles, polymer micelles, nanoemulsions, and metal nanoparticles, have shown promising results in improving the solubility and bioavailability of LUT. This is a significant step forward in enhancing the therapeutic potential of LUT in cancer treatment. Furthermore, the study found that LUT's ability to scavenge free radicals can significantly reduce the side effects of cancer treatment, further highlighting its potential to improve patient outcomes.Nanoformulations, because of their unique surface and physiochemical properties, improve the solubility and bioavailability of LUT. However, poor in-vitro and in-vivo correlation and scalability of nanoformulations need to be addressed to achieve good clinical performance of LUT in oncology.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.